초록 ▼

The present invention discloses a sandwich method and a kit for assaying interleukin-2 receptor (IL-2R) in a sample. The method comprises determining reactivity of said sample with a plurality of ligands, each said ligand having binding affinity for a specific site on the receptor, said site being d

The present invention discloses a sandwich method and a kit for assaying interleukin-2 receptor (IL-2R) in a sample. The method comprises determining reactivity of said sample with a plurality of ligands, each said ligand having binding affinity for a specific site on the receptor, said site being different for each said ligand and distinct from interleukin-2 binding site on the receptor. The invention also discloses a method of detecting such disturbed or abnormal conditions in humans which release soluble IL-2R in the body fluid.

대표청구항 ▼

A method for quantitative determination of soluble interleukin-2 receptor (IL-2R) leveL in a cell free sample comprising the steps of: (a) coating suitable number of wells in a multiwell microtiter plate with immunoglobulin containing antibody against soluble IL-2R; (b) washing the wells with a suit

A method for quantitative determination of soluble interleukin-2 receptor (IL-2R) leveL in a cell free sample comprising the steps of: (a) coating suitable number of wells in a multiwell microtiter plate with immunoglobulin containing antibody against soluble IL-2R; (b) washing the wells with a suitable medium to remove excess unbound antibody; (c) adding a sample of human body fluid suspected of containing soluble IL-2R to the wells and incubating for sufficient time for binding between antibody and said sample to occur; (d) washing the wells with suitable medium to remove unbound sample; (e) adding to the wells sufficient amount of fluoresceinisothiocyanate (FITC) modified monoclonal antibody against IL-2R, said monoclonal antibody being different from that in step (a) if the antibody in step (a) is also a monoclonal antibody, incubating for sufficient time for binding between the monoclonal antibody and said sample to occur; (f) washing the wells with suitable medium to remove unbound FITC modified antibody; (g) adding to the wells enzyme-conjugated anti-FITC antibody and incubating for sufficient time for binding to occur; (b) washing the wells with suitable medium to remove unreacted anti-FITC antibody and; (i) adding sufficient amount of suitable substrate for said conjugated enzyme and measuring for resulting product relative to known amounts of IL-2R similarly treated as in steps (a) thru (i) and then determining the level of binding between the soluble receptor and the FITC modified monoclonal antibody by comparing with a control sample or a standard curve.